Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Study to Evaluate HBI-8000 in Patients with Aggressive, Refractory or Relapsed, Advanced Peripheral T-Cell Lymphoma (PTCL) in Japan

Next Previous
X
Search
Trial Profile

A Phase 2b Study to Evaluate HBI-8000 in Patients with Aggressive, Refractory or Relapsed, Advanced Peripheral T-Cell Lymphoma (PTCL) in Japan

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tucidinostat (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors HUYA Bioscience International

    • Most Recent Events

    • 30 Nov 2021 Results presented in HUYABIO International media release
    • 30 Nov 2021 According to a HUYABIO International media release, the cmpany announced the regulatory approval of HBI-8000, brand name Hiyasta, monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan. This application of the supplemental indication for R/R PTCL is based on data from this study.
    • 08 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top